



## CORRECTIONS

# Communicating emerging risks of SGLT2 inhibitors—timeliness and transparency of medicine regulators

In this analysis (*BMJ* 2020;369:m1107, doi:10.1136/bmj.m1107, published 29 April 2020), one of the five serious risks of SGLT2 inhibitors was omitted—acute kidney injury. The full list is

diabetic ketoacidosis, lower limb amputation, severe genitourinary infections, acute kidney injury, and fracture. This has been amended online.